mounting evidence (via @DrScottHadland) that industry can and has influenced opioid prescribing-- still NO ACTION or even disclosure in British Columbia? cc @adriandix https://t.co/NEVvboe41G
.@DrScottHadland et al. with some more incredible work now in @JAMAInternalMed:
1 meal or more from pharma ($13 bucks) w/ likely higher rates of prescribing opioids
@purduepharma spending at a higher clip in Canada and still no halt on activity or disclosure
Why knock when the MDs (in the article) are holding the door wide open...
Or did they simply leave the door open when they were busy at the trough
@Open_Pharma#greed https://t.co/QkGEedW45T
industry: "there is already a code of ethics so no need for regulations/oversight" + "the transfers of value are harmless to patients"
but still: "five NYC docs received $100ks in strip club visits and dinners for prescribing a powerful opiate spray" https://t.co/WfpPlgsU8L
Ontario to bring in laws forcing #pharmaceutical and #medicaldevice makers, to report "donations" to doctors' groups and patient associations- here's the draft thanks @kellygrant1 https://t.co/oKsXxdln1E #transparency
@picardonhealth@kellygrant1@globeandmail@Open_Pharma@drandrewb Excellent. This is the best thing I have seen out of Ontario this year. As this spreads to other regions we can see all $ that @purduepharma is dumping into grassroots pain patient advocacy groups to do their own opioid marketing.
A new U.S. report finds that opioid-makers gave millions to patient advocacy groups. This kind of data is not public in Cda, but could be once Ontario passes its proposed transparency law, via @statnews https://t.co/E07Vak94q9
Another informative piece by my MA and PhD supervisor, Dr. Joel Lexchin. A worthwhile read for anyone who takes, or will ever take, medications. https://t.co/R6TJb1TUTP via @ConversationCA
inequality might insulate policymakers from everyday realities like drug costs. universal pharmacare can help reduce the disparity by giving Canadians the same access afforded elected officials --terrific @mtaglione@NavPersaud
Our paper in @ESPREVMED: https://t.co/2DrEhJAXk1